Maintain adequate hydration (1.52 litres daily), eat small frequent meals, rise slowly from sitting or lying positions, and monitor blood glucose levels if taking insulin or sulfonylureas
a , Cryo-EM data processing flow chart
EMA decision P/0336/2024 paediatric investigation plan for retatrutide
Pre-treatment: Measure morning resting heart rate for 5 days Calculate average baseline Record any existing caffeine or stimulant use During treatment: Measure resting heart rate 3 times weekly during dose escalation Continue at each dose for minimum 4 weeks before increasing If resting HR exceeds baseline by more than 15 BPM, hold dose for an additional 2 weeks If resting HR exceeds 100 BPM at rest on two or more measurements, consult physician Expected timeline: Weeks 1-8: minimal heart rate change at starting doses Weeks 8-24: gradual increase of 5-10 BPM at therapeutic doses Weeks 24+: stabilization and gradual decline toward baseline This is the approach most researchers follow successfully, and it aligns with the standard retatrutide dosing protocol used in clinical trials

The rationale is straightforward: a 120kg individual has significantly more tissue volume for the peptide to distribute through than a 70kg individual, which affects both the effective concentration at receptor sites and the perceived intensity of side effects